Latest Conference Articles

November 16th 2022, 2:00pm

SITC Meeting

The combination of sotigalimab and pembrolizumab showed encouraging antitumor activity and was well tolerated in the frontline setting of patients with metastatic melanoma.

November 14th 2022, 9:20pm

PER® New York Lung Cancer Symposium

Balazs Halmos, MD, discusses the importance of testing for HER2 mutations and exon 20 insertions, which are emerging new targets in non–small cell lung cancer, and how fam-trastuzumab deruxtecan-nxki meets needs for patients with HER2-mutant disease.

November 14th 2022, 9:10pm

PER® New York Lung Cancer Symposium

Mark G. Kris, MD, discusses the role of immunotherapy in patients with non–small cell lung cancer without driver mutations.

November 14th 2022, 8:55pm

PER® New York Lung Cancer Symposium

In treating patients with locally advanced non–small cell lung cancer, one must consider multiple factors when deciding whether to treat them with immunotherapy or a targeted approach, even though the optimal treatment sequence has yet to be definitively established.

November 14th 2022, 7:55pm

PER® New York Lung Cancer Symposium

Osimertinib remains the preferred first-line therapy for patients with EGFR-mutated non–small cell lung cancer. However, for those with classic EGFR mutations, the day is fast approaching when physicians will add chemotherapy to first-line treatment with the EGFR TKI based on ctDNA results.

November 14th 2022, 7:24pm

PER® New York Lung Cancer Symposium

Investigators are harnessing comprehensive molecular profiling to detect new targets, optimize existing treatment regimens, and develop novel therapies for patients with EGFR and MET exon 20–insertion positive non–small cell lung cancer.

November 13th 2022, 11:00am

SITC Meeting

CYNK-101 demonstrated synergistic activity when used in combination with avelumab through antibody-dependent cellular cytotoxicity against PD-L1–positive non–small cell lung cancer, triple-negative breast cancer, and bladder cancer cell lines, according to preclinical data.

November 12th 2022, 11:00am

PER® Chemotherapy Foundation Symposium (CFS)

Alan L. Ho, MD, PhD, discusses targeted therapies such as TKIs that have demonstrated promising efficacy in multiple patient populations as well as the agents lenvatinib and pembrolizumab.

November 12th 2022, 4:10am

LUGPA Annual Meeting

All patients with prostate cancer, except for those with low-risk or very low-risk localized disease, should be tested for germline mutations, and somatic testing should be done in all patients with metastatic disease as there are therapeutic implications.

November 11th 2022, 11:06pm

LUGPA Annual Meeting

For patients with metastatic castration-resistant prostate cancer who experience disease progression on novel hormonal agents (NHAs) and androgen deprivation therapy, it is important to consider when the NHA was received and whether docetaxel has been administered, as these factors affect downstream options and sequencing.

November 11th 2022, 9:25pm

PER® Chemotherapy Foundation Symposium (CFS)

Benjamin Philip Levy, MD, discusses potential future uses for atezolizumab in non–small cell lung cancer.

November 11th 2022, 9:01pm

LUGPA Annual Meeting

As the role of genetic testing in clinical practice becomes more prevalent for patients with prostate cancer to identify mutations, physicians must consider a variety of factors to determine which patients are candidates for somatic and/or germline testing.

November 11th 2022, 7:25pm

LUGPA Annual Meeting

Because androgen deprivation therapy alone or with docetaxel is not recommended for most patients with metastatic castration-sensitive prostate cancer, a decision must be made between leveraging couplets vs triplets.

November 11th 2022, 5:00pm

LUGPA Annual Meeting

David Albala, MD, discusses the key advantages of utilizing PSMA-PET screening in clinical practice for patients with prostate cancer.

November 11th 2022, 5:00pm

LUGPA Annual Meeting

Emmanuel Antonarakis, MD, discusses the different therapeutic agents that are available for patients with metastatic castration-resistant prostate cancer who display either somatic or germline mutations.

November 11th 2022, 5:00pm

LUGPA Annual Meeting

Neal Shore, MD, discusses the importance of incorporating genetic testing into treatment strategies for patients with prostate cancer.

November 11th 2022, 4:46pm

LUGPA Annual Meeting

David Albala, MD, discusses integrating PSMA-PET imaging into the clinic and determining which patients with prostate cancer are prime candidates.

November 11th 2022, 3:45pm

SITC Meeting

The first-line combination of pembrolizumab and eftilagimod alpha elicited a 40.4% (95% CI, 31.3%-50.0%) overall response rate by immune RECIST criteria in the intent-to-treat population in patients with advanced non–small cell lung cancer, according to updated findings from the phase 2 TACTI-002 trial.

November 11th 2022, 2:45pm

LUGPA Annual Meeting

Arlene O. Siefker-Radtke, MD, discusses the use of erdafitinib in urothelial carcinoma.

November 11th 2022, 2:25pm

PER® Chemotherapy Foundation Symposium (CFS)

Richard D. Carvajal, MD, discusses the prognostic factors of uveal melanoma that differentiate it from other subsets of melanoma.